Ionis Pharmaceuticals Inc (Nasdaq:IONS)
February 13th, 2019
With markets going up Ionis Pharmaceuticals Inc closed Wednesday up 1.47%, a $0.88 increase to close on $60.55. Furthermore it hit a new 52 week high of $60.92. It’s expected that Ionis Pharmaceuticals Inc will report earnings within the next couple of weeks.
Results from 14 analysts suggest that Ionis Pharmaceuticals Inc might decline somewhat (-7.62%), while Finbox has calculated (with medium uncertainty) a fair value price of $48.92.
The market sectors were mixed Wednesday with a majority of the sectors trending up. Energy saw the biggest increase of the day (1.29%), while Utilities saw the biggest drop (-0.31%). Industrials has seen the biggest year-to-date gain at 15.68%.
Energy saw the biggest turnaround from its 5-day performance of -1.99%, as it went up 1.29%. Utilities saw a turn around from its 5-day performance of 1.76% trading down -0.31%.
- Energy went up with a 1.29% change.
- Industrials went up with a 0.63% change.
- Consumer Discretionary went up with a 0.62% change.
- Real Estate went up with a 0.58% change.
- Consumer Staples went up with a 0.25% change.
- Healthcare went up with a 0.25% change.
- Financials went up with a 0.20% change.
- Information Technology went up with a 0.14% change.
- Materials went up with a 0.10% change.
- Communication Services went down with a -0.10% change.
- Utilities went down with a -0.31% change.
Ionis Pharmaceuticals Inc Info
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer’s and Parkinson’s diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington’s disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases; Roche to develop therapeutics for the treatment of complement-mediated diseases; and drug research collaboration with SRI International for the intracellular delivery of nucleic acid-based drugs, as well as a research collaboration agreement with Cerveau Technologies, Inc. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.